Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Isehara-shi
Clinical trial register · Japan

Clinical Trials in Isehara-shi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2517 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:19 UTC
2517
Studies in scope
all four open statuses
1288
Recruiting now
open to new participants
355
Lead sponsors
across recruiting studies
Top sites
Fukuoka 558 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354

Trials with a site in Isehara-shi

25 of 2517 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,600
Isehara-Shi, Shinjuku, Ube
2026-08-26
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,120
Tōon, Ōta, Akashi, Kita-gun, Isehara-Shi, Kyoto, Sendai, Chuo
2026-03-09
Recruiting
AstraZeneca
Phase 3
800
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku
2025-08-01
By invitation
Comparison of Three-sided and Single-sided Mattress Pancreaticojejunostomy in Pancreatoduodenectomy
NCT06855888Postoperative Pancreatic Fistula Post-pancreatoduodenectomy
Tokai University
Not applicable
80
Isehara-shi
2024-12-10
Active, closed
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
NCT06547528Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ono Pharmaceutical Co., Ltd.
Phase 1
108
Nagoya, Akita, Kashiwa-shi, Fukuoka, Sapporo, Isehara-shi, Kumamoto, Kyoto
2023-10-01
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Shibukawa-shi, Kamakura-Shi, Kumamoto, Sunto-gun, Chiba, Gifu, Hiroshima, Isehara-shi
2023-06-22
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Active, closed
TRISCEND JAPAN Study
NCT05760989Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
53
Kitakyushu-shi, Isehara-shi, Sendai, Osaka, Suita, Suita-shi, Shinjuku-Ku
2023-02-06
Recruiting
AstraZeneca
Phase 3
3,527
Chiba, Fukuoka, Gifu, Ginowan-shi, Hanyu-shi, Hiroshima, Hitachi-shi, Isehara-shi
2022-12-13
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Chiba, Fukushima, Higashimatsuyama-shi, Isehara-shi, Kawasaki-shi, Morioka, Nagasaki, Nagoya
2022-11-21
Active, closed
AstraZeneca
Phase 3
368
Akita, Fukuoka, Himeji, Hiroshima, Isehara-shi, Kawasaki-shi, Maebashi, Minatoku
2022-11-10
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
Kashiwa-shi, Yoshida-gun, Fukushima, Isehara-shi, Nagasaki, Bunkyo-ku, Bunkyō City, Fukuoka
2022-02-28
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Isehara-Shi, Kumamoto-Shi Chuo-Ku, Naha, Osaka-Shi Chuo-Ku, Shinden, Koto-Ku, Fukushima, Hiroshima
2021-08-27
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,371
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Active, closed
AstraZeneca
Phase 3
370
Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama
2020-10-02
Active, closed
AstraZeneca
Phase 3
1,012
Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi
2020-07-13
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto
2019-11-13
Active, closed
AstraZeneca
Phase 3
1,837
Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa
2014-04-22
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 November 2026. https://priyalifescience.com/clinical-trials-japan/city/isehara-shi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,517 studies in total at the last sync on 15 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Isehara-shi.

How many clinical trials are recruiting in Isehara-shi?

9 of the 25 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Isehara-shi), 25 studies
PhaseStudiesRecruitingShare
Phase 320880%
Not applicable208%
Phase 1104%
Phase 1/2114%
Phase 2104%

Most active sponsors

Lead sponsors with the most studies (Isehara-shi)
Lead sponsorStudiesRecruiting
AstraZeneca156
Regeneron Pharmaceuticals32
Alexion Pharmaceuticals, Inc.10
Bristol-Myers Squibb10
Edwards Lifesciences10
Hoffmann-La Roche10
Ono Pharmaceutical Co., Ltd.10
Sumitomo Pharma America, Inc.11
Tokai University10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.